New technology promises a growing choice of diagnosis and treatment options for heart disease
This article was originally published in Clinica
In this second part of a review of the report from the non-profit health technology assessment agency ECRI, the focus is on heart disease. Phil Greenfield looks at the rapidly increasing range of new technologies aimed at combating heart disease.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.